News

The company said that an epilepsy medication is a natural extension to its product line. The prevalence of migraine in people who experience epilepsy is 8.4 to 20%,

In the European Union (EU), defibrotide is marketed by Jazz Pharmaceuticals under the name Defitelio for the treatment of severe hepatic veno-occlusive disease (VOD) in patients over one

This new license agreement provides the rights for the Company’s development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in

The company said that oral pirfenidone (Esbriet) has shown promise to slow IPF disease progression and a very large oral dose is required to achieve efficacious lung levels.

Every year in the US and Europe, two to three out of every 100,000 people are diagnosed with glioblastoma multiforme, which has a five year survival rate of

The FDA approval expands the company’s Flexbumin product portfolio to include both 5% in a 250mL solution and 25% in 50 and 100mL solutions. Flexbumin is the first

In December 2013, Apricus expanded its exclusive license agreement with Hexal, an affiliate within Sandoz, for the commercialization of Vitaros in Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the

The new jointly-owned enterprise will work with researchers at the US university research institutions to identify discoveries that have therapeutic and commercial potential. Allied-Bristol Life Sciences will also

At the conclusion of the inspection, the FDA issued a Form 483 with seven inspectional observations, two of which are designated as repeat observations. The FDA did not